Imfinzi plus tremelimumab demonstrated promising clinical activity and tolerability in patients with advanced liver cancer
Data presented at ASCO showed patients treated with a single, priming dose of tremelimumab plus Imfinzi achieved longest median survival among regimens testedResults from the global Phase II Study 22 trial testing AstraZeneca’s tremelimumab, an anti-CTLA4 antibody, added to Imfinzi (durvalumab) demonstrated promising clinical activity and tolerability in patients with advanced hepatocellular carcinoma (HCC). HCC is the most common type of liver cancer.[1] In the primary endpoint of the trial evaluating safety, all experimental arms demonstrated an acceptable profile and no new safety